Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Dengvaxia Market Size, Value And Growth Trajectory Through 2030
The dengvaxia market has experienced swift expansion in recent times. Projections indicate it will surge from $213.36 million in 2025 to $250.81 million by 2026, achieving a compound annual growth rate (CAGR) of 17.6%. This historical growth is attributable to recurrent dengue outbreaks, the significant disease burden prevalent in tropical regions, government-led immunization drives, the scarcity of treatment alternatives for dengue, and increasing public health knowledge.
The dengvaxia market is anticipated to experience significant expansion over the coming years, with projections indicating it will reach **$473.95 million by 2030, displaying a compound annual growth rate (CAGR) of 17.2%.** This growth during the forecast period is primarily driven by wider vaccination coverage, the escalating spread of mosquitoes influenced by climate change, increased public health funding, enhanced vaccine delivery infrastructure, and a growing demand for travel-related immunizations. Prominent trends expected in this timeframe include the expansion of dengue vaccination programs, a heightened focus on preventing endemic diseases, an increase in public health immunization campaigns, intensified surveillance of mosquito-borne illnesses, and the reinforcement of pediatric and adolescent vaccination efforts.
Get A Free Sample Report With In-Depth Market Insights:
Dengvaxia Market Growth Backed By Core Demand Fundamentals
The elevated occurrence of dengue is anticipated to fuel the expansion of the dengvaxia market. Dengue is a viral infection transmitted by Aedes mosquitoes, manifesting with flu-like symptoms, intense pain, and potentially leading to severe, life-threatening complications such as dengue hemorrhagic fever or dengue shock syndrome. Its rising prevalence stems from factors like climate change, urban expansion, greater travel, and proliferating mosquito habitats, resulting in higher infection rates and an increased need for prevention and treatment. Dengvaxia offers protection against dengue as an effective vaccine that prompts the immune system to develop a defensive reaction against the virus, thereby lowering the chances of infection and severe complications and improving public health results in endemic areas. For example, in June 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that the Americas recorded over 9.7 million dengue cases, which is double the 4.6 million cases seen in 2023. Puerto Rico issued a public health emergency due to 1,498 cases, while 745 cases were identified among U.S. travelers. Consequently, the widespread incidence of dengue is propelling the growth of the dengvaxia market. The increasing trend of global travel is anticipated to boost the expansion of the dengvaxia market. International travel involves journeys undertaken across national borders for various reasons, including leisure, commerce, or study. Such elevated travel heightens the potential for the dissemination of infectious diseases, including dengue, thereby increasing the need for preventative solutions such as vaccines. Dengvaxia is utilized amidst growing international travel to safeguard individuals from acquiring dengue in areas where it is common and to mitigate the spread of the disease beyond national boundaries. For instance, in May 2024, the UK’s Office for National Statistics, a UK-based government department, reported that international visits to the UK in 2023 significantly rose from 31.2 million in 2022 to 38.0 million. Consequently, the surge in international travel will contribute to the growth of the dengvaxia market.
Dengvaxia Market Segment Analysis: What Are The Core Market Categories?
The dengvaxia market covered in this report is segmented –
1) By Type: Dengvaxia, Other Types
2) By Distribution Channel: Hospitals, Clinics, Public Health Programs
3) By Clinical Indication: Prevention In Previously Infected Individuals, Protection In High-Risk Regions, Traveler Immunization, Pediatric And Adolescent Use
Dengvaxia Market Top Companies Driving Competitive Growth
Major companies operating in the dengvaxia market are Sanofi Pasteur Inc.
View The Full Dengvaxia Market Report:
Dengvaxia Market Largest Region By Revenue And Market Share
Asia-Pacific was the largest region in the dengvaxia market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengvaxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
